Related Experiment Video

Updated: Jul 13, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international,

D Posthouwer1, T T Yee, M Makris

  • 1Van Creveldkliniek, University Medical Center, Utrecht, The Netherlands.

Journal of Thrombosis and Haemostasis : JTH
|August 1, 2007
PubMed

Insights

Antiviral therapy for hepatitis C in hemophilia patients achieved sustained virological response (SVR) in up to 63% of cases. Successful treatment significantly reduced the risk of end-stage liver disease (ESLD) long-term.

Area of Science:

  • Hepatology
  • Virology
  • Hematology

Background:

  • Hepatitis C virus (HCV) infection is a significant comorbidity in individuals with hemophilia.
  • Limited data exists regarding the long-term efficacy and outcomes of antiviral treatments for HCV in this population.

Purpose of the Study:

  • To evaluate the effectiveness of interferon-based (IFN-based) therapies in achieving HCV eradication.
  • To identify factors influencing treatment response.
  • To assess the incidence of end-stage liver disease (ESLD) post-treatment.

Main Methods:

  • A multicenter cohort study included 295 treatment-naïve hemophilia patients with chronic HCV infection.
  • Sustained virological response (SVR) was the primary measure of treatment efficacy.
  • Odds ratios (ORs) were used to determine factors associated with treatment response, and Kaplan-Meier survival analysis assessed ESLD cumulative incidence.

Main Results:

  • SVR rates varied by treatment regimen and HIV co-infection status, reaching 63% with pegylated IFN (PegIFN) and ribavirin in HIV-negative patients.
  • HCV genotypes 2 and 3, and combination therapies (IFN/ribavirin or PegIFN/ribavirin) were associated with higher SVR rates.
  • No relapses or ESLD occurred in patients achieving SVR up to 15 years post-treatment, whereas unsuccessfully treated patients had a 13.0% cumulative incidence of ESLD.

Conclusions:

  • Effective antiviral therapy provides a lasting benefit for hemophilia patients with HCV.
  • Achieving SVR significantly mitigates the long-term risk of developing end-stage liver disease.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...